Compare CYTK & ALGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | ALGN |
|---|---|---|
| Founded | 1997 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 12.7B |
| IPO Year | 2004 | 2000 |
| Metric | CYTK | ALGN |
|---|---|---|
| Price | $76.84 | $174.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 12 |
| Target Price | $89.26 | ★ $199.82 |
| AVG Volume (30 Days) | ★ 1.7M | 847.0K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.53 |
| EPS | N/A | ★ 3.09 |
| Revenue | $13,368,000.00 | ★ $387,126,000.00 |
| Revenue This Year | $7.37 | $5.78 |
| Revenue Next Year | $310.19 | $4.62 |
| P/E Ratio | ★ N/A | $57.10 |
| Revenue Growth | N/A | ★ 23.95 |
| 52 Week Low | $34.60 | $122.00 |
| 52 Week High | $88.31 | $200.44 |
| Indicator | CYTK | ALGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.54 | 49.38 |
| Support Level | $73.95 | $164.70 |
| Resistance Level | $79.66 | $180.17 |
| Average True Range (ATR) | 2.91 | 6.68 |
| MACD | -0.37 | 0.18 |
| Stochastic Oscillator | 33.77 | 37.47 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.